Skip to main content
logo
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.350
+0.040 (3.05%)
At close: May 22, 2026, 4:00 PM EDT
1.352
+0.002 (0.15%)
After-hours: May 22, 2026, 7:01 PM EDT

Metagenomi Therapeutics Revenue

Metagenomi Therapeutics had revenue of $1.25M in the quarter ending March 31, 2026, a decrease of -69.76%. This brings the company's revenue in the last twelve months to $22.33M, down -50.66% year-over-year. In the year 2025, Metagenomi Therapeutics had annual revenue of $25.21M, down -51.79%.

Revenue (ttm)
$22.33M
Revenue Growth
-50.66%
P/S Ratio
2.28
Revenue / Employee
$187,655
Employees
119
Market Cap
50.82M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202525.21M-27.09M-51.79%
Dec 31, 202452.30M7.54M16.84%
Dec 31, 202344.76M27.56M160.21%
Dec 31, 202217.20M16.96M6,978.19%
Dec 31, 2021243.00K--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Gossamer Bio55.54M
Xilio Therapeutics53.48M
Radiopharm Theranostics10.86M
Plus Therapeutics5.18M
Hyperion DeFi1.04M
aTyr Pharma190.00K
Revenue Rankings

MGX News

More News